Free Trial

Cerena Chen Analyst Performance

Analyst at Wells Fargo & Company

Cerena Chen is a stock analyst at Wells Fargo & Company focused in the medical sector, covering 3 publicly traded companies. Over the past year, Cerena Chen has issued 4 stock ratings, including buy and hold recommendations. While full access to Cerena Chen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Cerena Chen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
50.00% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy50.0%2 ratings
Hold50.0%2 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Cerena Chen at Wells Fargo & Company, the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Cerena Chen, an analyst at Wells Fargo & Company, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
66.7%
Computer and Technology
1 company
33.3%

Cerena Chen of Wells Fargo & Company specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
SOFTWARE - APPLICATION
1 company
33.3%

Cerena Chen's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Strategy Inc stock logo
MSTR
Strategy
9/30/2025Reiterated Rating$326.42$54.00Equal Weight
Metsera Inc. stock logo
MTSR
Metsera
9/30/2025Downgrade$52.10$54.00Equal Weight
Metsera Inc. stock logo
MTSR
Metsera
6/20/2025Initiated Coverage$27.71$65.00Overweight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
5/6/2025Reiterated Rating$115.68$165.00Overweight